IR call - Acquisition of Bioverativ Inc.

Sanofi will acquire Bioverativ Inc., a biopharmaceutical company focused on therapies for hemophilia and other rare blood disorders. Sanofi hosted a conference call & webcast on the acquisition for the financial community.

(14h00 CET / 8:00am ET)


Call transcript


Press release - January 22, 2018: Sanofi to Acquire Bioverativ for $11.6 Billion